Results 41 to 50 of about 1,497,867 (353)

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer

Scientific Reports
FOXA1 is a pioneer transcription factor that is frequently mutated in prostate, breast, bladder, and salivary gland malignancies. Indeed, metastatic castration-resistant prostate cancer (mCRPC) commonly harbour FOXA1 mutations with a prevalence of 35 ...
Kevin J. Tam, Liangliang Liu, Michael Hsing, Kush Dalal, Daksh Thaper, Brian McConeghy, Parvin Yenki, Satyam Bhasin, James W. Peacock, Yuzhuo Wang, Artem Cherkasov, Paul S. Rennie, Martin E. Gleave, Christopher J. Ong   +13 more
doaj   +1 more source

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors

Cells, 2022
The mutation-driven transformation of clinical anti-androgen drugs into agonists of the human androgen receptor (AR) represents a major challenge for the treatment of prostate cancer patients. To address this challenge, we have developed a novel class of
Mariia Radaeva, Huifang Li, Eric LeBlanc, Kush Dalal, Fuqiang Ban, Fabrice Ciesielski, Bonny Chow, Helene Morin, Shannon Awrey, Kriti Singh, Paul S. Rennie, Nada Lallous, Artem Cherkasov   +12 more
doaj   +1 more source

Is birthweight associated with total and aggressive/lethal prostate cancer risks? A systematic review and meta-analysis [PDF]

, 2016
BACKGROUND: It has been hypothesised that intrauterine exposures are important for subsequent prostate cancer risk. Prior epidemiological studies have used birthweight as a proxy of cumulative intrauterine exposures to test this hypothesis, but results ...
Cook, Michael B, Hardy, Rebecca, Kuh, Diana, Mackinnon, Karen, Sutcliffe, Siobhan, Welsh, Judith, Zhou, Cindy Ke   +6 more
core   +3 more sources

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review

BJUI Compass
Objective To analyse the latest evidence on the relative harms and benefits of screening and diagnostic pathways with close examination of (i) men aged 50 years or older, (ii) men whose ethnicity places them at higher risk and (iii) men with a family ...
Abel Tesfai, Natalia Norori, Thomas A. Harding, Yui Hang Wong, Matthew David Hobbs   +4 more
doaj   +1 more source

Improvement of quality of life and symptom burden after robot-assisted radical prostatectomy in patients with moderate to severe LUTS

Scientific Reports, 2021
The aim of this study was to assess clinically meaningful differences of preoperative lower urinary tract symptoms (LUTS) and quality of life (QoL) before and after robot-assisted radical prostatectomy (RARP).
Sami-Ramzi Leyh-Bannurah, Christian Wagner, Andreas Schuette, Nikolaos Liakos, Theodoros Karagiotis, Mikolaj Mendrek, Pawel Rachubinski, Katarina Urbanova, Matthias Oelke, Jorn H. Witt   +9 more
doaj   +1 more source

Sexual well-being and diurnal cortisol after prostate cancer treatment. [PDF]

, 2020
Sexual dysfunction and psychological distress are common after prostate cancer. Research has not examined the role of neuroendocrine markers of stress (e.g. cortisol).
Gaffey, Allison E, Hoyt, Michael A, Lawsin, Catalina J, Litwin, Mark S, Wang, Ashley W   +4 more
core  

Advances in targeted Alpha therapy for prostate cancer [PDF]

, 2019
BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity.
De Vincentis, G, Gerritsen, W, Gschwend, JE, Hacker, M, Lewington, V, O'Sullivan, JM, Oya, M, Pacilio, M, Parker, C, Sartor, O, Shore, N, Targeted Alpha Therapy Prostate Working Group   +11 more
core   +2 more sources

Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients. [PDF]

, 2020
ObjectivesDevelopment and pilot evaluation of a personalized decision support intervention to help men with early-stage prostate cancer choose among active surveillance, surgery, and radiation.MethodsWe developed a decision aid featuring long-term ...
Belkora, Jeffrey, Broering, Jeanette M, Carroll, Peter R, Chan, June M, Cooperberg, Matthew R, Cowan, Janet E, Kenfield, Stacey A, Neuhaus, John, Rosenfeld, Stan, Simko, Jeffry P, Stupar, Lauren, Tenggara, Imelda, Van Blarigan, Erin L, Weinberg, Tia, Witte, John   +14 more
core   +1 more source